21st February 2020 – The Preimplantation
Genetic Testing (PGT) Market report provides in-depth analysis and
insights into developments impacting businesses and enterprises on global and
regional level. The study covers the global Preimplantation Genetic Testing
(PGT) Market presentation regarding revenue contribution from multiple segments
and covers a comprehensive analysis of key market trends, drivers, restraints,
and opportunities influencing revenue growth of the industry. This research
report studies the market size, industry status and forecast, competition
landscape and growth opportunities.
The global preimplantation genetic
testing (PGD/PGT) market is expected to value at USD 221.1 million by 2024. The
market is subject to witness a substantial growth due to the rising awareness
in regards to genetic techniques and increasing adoption for detection of
chromosomal abnormalities. Use of preimplantation genetic testing (PGD/PGS) for
embryo screening to perform in vitro fertilization (IVF) is expected to boost
market growth over the forecast period. Identification of genetic disorders and
inherited conditions with the help of preimplantation genetic testing (PGT) and
diagnosis is predicted to foster market growth over the upcoming years.
Request
a Sample Copy @ https://www.millioninsights.com/industry-reports/preimplantation-genetic-testing-market/request-sample
Globally, the preimplantation genetic
testing industry is predicted to grow at higher CAGR in the forecast period,
providing numerous opportunities for market players to invest for research and
development in the preimplantation genetic testing market. Early diagnosis of
the chromosomal disorders helps to reduce the number of people suffering from
congenital diseases. These factors are anticipated to fuel demand for
preimplantation genetic testing (PGT) solutions. Increasing number of
incidences of various gene-related disorders is estimated to favor market
growth over the next seven years.
Genetic testing identifies differences
among genes that are related with disease or other behaviors. The genetic tests
determine person susceptibility towards genetic disease. The testing also helps
to understand the likelihood of a person to carry forward genetic mutation to
their offspring. Preimplantation genetic testing is performed on various blood
sample taken during different period in person’s life, for example, before the
birth and until death of the individual. The fast paced technological
advancement in genetic testing and sequencing methodologies, has led to the
vast expansion of genetic testing in numerous health care sections to determine
individual’s susceptibility towards complex disorders.
Pre-implantation genetic diagnosis (PGD
or PIGD) is also referred as the genetic profiling of embryos prior to
implantation. Pre-implantation genetic diagnosis (PGD or PIGD) is also used for
profiling of oocytes prior to fertilization. Pre-implantation genetic diagnosis
is carried out in similar way as that of prenatal diagnosis. Pre-implantation
genetic diagnosis offer benefits such as selective pregnancy termination thus
ensuring the baby will be free of the disease under consideration.
Pre-implantation genetic diagnosis uses in vitro fertilization (IVF) to achieve
oocytes or embryos for evaluation.
The preimplantation genetic testing
(PGT) industry is broadly categorized into four major segments based on the
application type such as embryo HLA typing for stem cell therapy, IVF
prognosis, late-onset genetic disorders, and inherited genetic disease. The
embryo HLA typing for stem cell therapy is considered as one of the fastest
growing segment in the preimplantation genetic testing (PGT) market with
substantial revenue generation in the last few years.
Growing popularity of preimplantation
genetic testing in the embryo HLA typing for stem cell therapy segment is
attributed to increasing implementation of the hematopoietic stem cell
transplantations via matched donors and significant improvements in overall
survival rate.
The preimplantation genetic testing
industry is divided by region as North America, Europe, Asia-Pacific, Latin
America and Africa. North America has shown major growth in recent years owing
to the rise in the implementation of latest technologies in medicine &
pharmaceutical sector, increase in the number of research & development
activities in the region, and existence of well-established healthcare
infrastructure.
Asia-Pacific region is predicted to hold
major market share in the preimplantation genetic testing market with massive
growth in forecast period. Countries such as Japan, China and South Korea are
leading the Asia-Pacific market with rising healthcare expenditure, strong
economic region, and significant investment by leading industry players
considering potential growth opportunities in the region.
Some of the major objectives of this
report:
·
To present detailed analysis of
the market structure along with forecast of the various segments and
sub-segments of global Preimplantation Genetic Testing (PGT) Market.
·
To provide insights about
factors affecting the market growth. To analyze the Preimplantation Genetic
Testing (PGT) Market based on various factors- price analysis, supply chain
analysis, porter five force analysis etc.
·
To provide historical and
forecast revenue of the Preimplantation Genetic Testing (PGT) Market segments
and sub-segments with respect to four main geographies and their countries-
North America, Europe, Asia, and Rest of the World.
·
To provide country level
analysis of the market for segment by application, product type and
sub-segments.
·
Trace and analyze competitive
developments such as joint ventures, strategic alliances, mergers and
acquisitions, new product evolutions, and research and developments in the
Market.
·
To present strategic profiling
of key players in the market, comprehensively analyzing their basic
capabilities.
Some
of the Major Market Players Are:
Quest Diagnostics, Inc.,
Reproductive Health Science Ltd., Natera, Inc., Cooper Surgical, Inc., Genea
Ltd., Good Start Genetics, Inc., Lab Co., California Pacific Medical Center,
Thermo Fisher Scientific, Inc., Bioarray S.L., Illumina, Inc., Igenomix Co.,
Reproductive Genetic Innovations LLC, F. Hoffmann-La Roche AG, and CombiMatrix
Co.
At Million Insights, we work with the
aim to reach the highest levels of customer satisfaction. Our representatives
strive to understand diverse client requirements and cater to the same with the
most innovative and functional solutions.
For
More Information, Visit @ https://www.millioninsights.com
No comments:
Post a Comment